Is telehealth revenue really recurring?

Many models are structured that way. Patients on ongoing therapies can pay monthly for medication and follow-up, creating refill-driven revenue when they remain active. True recurrence depends on billing mechanics, clinical appropriateness, fulfillment reliability, and whether patients stay past the first cycle. A clinic can look recurring in marketing while behaving like re-order in data if patients must manually repurchase each month and drop off silently. Buyers examine cohort retention and payment schedules, not landing page copy. Weight-health, hormone therapy, and mental health subscriptions are common examples where recurrence is intentional when operations support it.

What monthly prices are common?

Cash-pay digital clinic menus often land in the low hundreds per month depending on therapy, consult intensity, and medication COGS. Figures around $200 to $400 appear frequently in public pricing for certain weight-health and related categories, but they are not universal. Lower tiers may exclude medication and charge separately; higher tiers bundle consults and shipping. Insurance billing changes the patient-facing number entirely. For underwriting, use gross margin after fulfillment and consult costs, not sticker price alone. Competitive pressure and manufacturer pricing also move consumer willingness to pay over time.

What matters more, new patients or retention?

Both, but retention determines whether growth becomes durable cash flow and a sellable multiple. New patients expand the base and recover acquisition spend only if cohorts stay long enough. A clinic that buys traffic aggressively while leaking month-two refills is buying revenue, not building an asset. Sophisticated operators optimize onboarding, pharmacy speed, and follow-up cadence as seriously as creative testing. At exit, buyers often discount top-line from clinics with shallow retention even when growth looks impressive on a trailing-twelve-month chart. The question is not growth vs retention; it is whether growth sticks.

Why Telehealth Clinics Can Be Recurring-Revenue Assets

Many telehealth models bill monthly for ongoing therapies patients refill over time, which creates a different cash-flow profile than one-time procedural practices or project-based services. When cohort retention is healthy, revenue repeats without re-acquiring the same patient from zero every month. This article explains how refill-driven economics work, why retention drives enterprise value, how buyers diligence LTV and CAC together, and where operators misread "recurring" as automatic.

Get Started

What makes the revenue recurring?

In clinically supervised medication programs, patients often pay for an initial consult and then continue on a monthly cadence for medication and follow-up. Industry operator disclosures and cash-pay clinic menus commonly show monthly price points in the low hundreds of dollars depending on therapy and fulfillment model. Illustrative ranges discussed by digital clinics frequently fall around $200 to $400 per month for certain weight-health or similar programs, though exact pricing varies widely.

The economic point is structural: when clinically appropriate patients stay on therapy, revenue repeats without re-acquiring the same patient from zero every month. That resembles subscription software or membership models more than episodic urgent care, though churn is tied to clinical outcomes, side effects, and fulfillment quality, not only product preference.

Recurring vs re-order: a useful distinction

True recurring billing: Stored payment method charges on a schedule until pause or cancel.
Re-order without subscription: Patient must actively repurchase each cycle; looks recurring in aggregate but leaks more easily.
Payer-driven continuity: Insurance refill behavior differs from cash-pay subscription UX.

Buyers map cohort curves to see which pattern a clinic actually runs. Marketing language says "subscription"; bank deposits reveal the truth.

How does retention change the asset?

Assume a simplified example used for education, not a projection: 100 active patients, $250 average monthly recurring revenue, and 75% annual retention of the cohort. Monthly recurring revenue is about $25,000 before cost of goods and media. If retention falls to 40%, the same acquisition engine leaks cash because CAC must be recovered in fewer months.

Retention is the silent enterprise-value driver. Two clinics with identical top-line growth can diverge sharply in profitability and sellability based on month-three and month-six cohort behavior. GLP-1 and weight-health traffic spikes made this visible: brands that looked hot on first-month revenue still failed diligence when curves flattened.

Variables buyers stress-test

Average monthly revenue per active patient after discounts and refunds
Cohort retention at 30, 90, 180, and 365 days
Refill success rate and pharmacy turnaround time
Support ticket volume around side effects and billing disputes
Concentration in one medication or one traffic channel

Deep retention tactics are covered in patient retention in subscription telehealth.

Key takeaway: Acquisition opens the door. Retention turns visits into an asset buyers can underwrite.

Get Started

How is this different from a services business?

Agency retainers churn when the client fires you.
One-time procedural clinics restart demand every case.
Subscription telehealth compounds when refill behavior and clinical follow-up are designed into the portal.

Buyers of digital health assets often diligence LTV, CAC, refill rates, and compliance posture for this reason. A procedural dermatology practice can be excellent but still sells on multiples tied to provider hours and local reputation. A telehealth clinic with strong cohorts sells closer to a productized recurring model when documentation is clean.

Where the model comes from: category tailwinds

Recurring economics did not appear in a vacuum. Broader virtual care adoption after COVID created patients comfortable with portal refills. McKinsey and similar researchers framed large virtualizable spend pools. Weight-health and GLP-1 demand, described in our GLP-1 telehealth boom piece, accelerated monthly medication programs. Market size context is in U.S. telehealth market size in 2026.

Tailwinds help acquisition. They do not fix leaky operations. Recession-period behavior for sticky categories is discussed in telehealth during recessions.

Unit economics in plain language

LTV is roughly average monthly gross profit per patient multiplied by expected months retained. CAC is fully loaded acquisition cost including creative, media, and consult costs for patients who do not convert to refill. When LTV exceeds CAC with payback inside an acceptable window, the clinic can scale. When retention shortens, payback never arrives despite rising revenue.

Gross margin matters as much as top-line ARPU. Medication COGS, provider consult fees, shipping, and support load subtract from that $200 to $400 headline. Operators who quote revenue without margin often surprise buyers in diligence.

Operational levers that protect recurrence

Automated refill reminders tied to clinical cadence
Fast pharmacy fulfillment and proactive delay communication
Clear titration protocols and nurse or provider touchpoints
Billing transparency to reduce chargebacks
Multi-state provider coverage so patients do not churn on relocation

Benchmarks buyers use in diligence

There is no single public comp table for private telehealth clinics, but recurring-revenue buyers consistently ask for the same building blocks. They want trailing new-patient volume by channel, fully loaded CAC, average revenue per active patient, gross margin after medication and consult costs, and cohort retention at standard intervals. They compare payback months implied by those figures against their cost of capital and risk tolerance.

Healthy clinics show improving or stable later-month retention once onboarding kinks are fixed. Unhealthy clinics show a cliff after month one or heavy dependence on perpetual discounting to prevent cancel. Refund and chargeback rates belong in the same conversation because they erode net revenue per patient silently.

Compliance artifacts ride alongside financials. LegitScript status, advertising account history, pharmacy agreements, and clinical protocol documentation signal whether recurrence can scale without policy interruption. A recurring revenue chart with suspended ad accounts is not an asset yet.

Common operator mistakes with "recurring" models

Counting first payment as LTV

First checkout success is not lifetime value. Many weight-health funnels convert aggressively then lose patients who never receive a second shipment or who cancel after side effects without support.

Ignoring pharmacy latency

Delayed fulfillment drives cancels that look like demand problems in marketing dashboards but are operations problems in reality.

Single-channel acquisition

One ad account or one influencer deal is not a durable engine. Buyers discount recurrence that depends on a fragile traffic source.

Exit and transferability

Recurring revenue only becomes a sellable asset when ownership is transferable: entity, brand, funnels, ad accounts, processor relationships, patient data rights, and compliance files. Messy founder-personal accounts turn recurring cash flow into a lifestyle job, not an acquirable company. Exit framing is covered in what makes a telehealth clinic exit-ready. Capital comparison with brick-and-mortar models is in telehealth vs traditional healthcare investing.

How to model recurrence in a spreadsheet without fooling yourself

Start with active patients, not cumulative signups. Apply monthly churn derived from cohort data, not optimism. Subtract refunds and failed payments. Apply gross margin, not headline price. Layer CAC by channel with creative refresh costs included. If payback extends beyond your risk tolerance, the clinic is a trade, not an asset.

Scenario-test supply shocks and ad pauses. Recurring models feel safe until a pharmacy delay or policy suspension cuts refills for two weeks. Stress tests reveal whether recurrence is operational or rhetorical.

Why buyers pay attention to refill-driven clinics

Strategic acquirers and independent operators hunt models where revenue scales with patient continuity rather than constant re-acquisition. Refill-driven telehealth can fit that profile when cohorts prove stable. The multiple conversation starts only after retention tables, margin bridges, and compliance files match the marketing story.

Connecting recurrence to market context

Virtual care adoption after COVID, McKinsey's virtualizable spend framing, and GLP-1-driven patient inflow all expanded the pool of patients willing to pay monthly online. None of that removes the operator's job: prove that month two through month six revenue stays predictable enough to call the clinic an asset rather than a campaign.

Key takeaways

Monthly medication programs can create refill-driven recurring revenue when retention holds.
Illustrative consumer price bands often sit in the low hundreds per month, varying by therapy.
Retention quality dominates long-term enterprise value more than vanity top-line.
Buyers diligence LTV, CAC, refill rates, margin, and compliance together.
Category tailwinds help acquisition but do not replace cohort discipline.
Recurring revenue is a model trait, not an automatic outcome.